SuperworthCocrystal Pharma COCP
- Market cap
- $18.3M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Cocrystal Pharma's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $225K | $105K | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $4.2M+8% | $4.3M+30% | $3M−25% | $4.3M+54% | $3.2M−23% | $2M−52% | $1.4M−54% | $1.1M−74% | $954K−71% | $1.6M−21% | $1.4M+1% | $2.1M+91% |
| SG&A | $1.8M+2% | $1.4M+15% | $1.2M+0% | $1.1M−26% | $1.8M−3% | $1.2M−15% | $981K−19% | $986K−14% | $1.1M−37% | $862K−28% | $1.2M+23% | $1.1M+16% |
| −$4.4M−22% | −$4.7M+4% | −$4.2M−19% | −$5.4M+26% | −$5M+14% | −$3.2M−31% | −$2.3M−44% | −$2.1M−61% | −$2.1M−59% | −$2.5M−23% | −$2.4M+1% | −$3.2M+51% | |
| Interest expense | −$320K | −$180K | −$220K | −$151K+8% | −$111K−65% | −$55K−69% | −$37K−83% | −$28K−82% | −$22K−80% | −$47K−15% | −$22K−41% | −$10K−64% |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$4.2M−27% | −$4.5M−1% | −$4M−24% | −$5.3M+28% | −$4.9M+19% | −$3.3M−27% | −$2.3M−42% | −$2.1M−62% | −$2M−59% | −$2.4M−26% | −$2.3M−0% | −$3.2M+54% |
| −$0.41−41% | −$0.44−20% | −$0.39−39% | −$0.53+29% | −$0.49+20% | −$0.32−27% | −$0.23−41% | −$0.20−62% | −$0.19−61% | −$0.18−44% | −$0.17−26% | −$0.23+15% | |
| 10.2M+25% | 10.2M+25% | 10.2M+25% | 10.2M+1% | 10.2M+0% | 10.2M−0% | 10.2M+0% | 10.2M+0% | 11M+8% | 13.8M+36% | 13.8M+36% | 13.8M+36% |
EPS, diluted: 19 periods, Q1 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q4 FY11 to Q4 FY17: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY13: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x1.266). 9 periods, Q4 FY14 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY16: a loss quarter: its basic count, share-days: the 12-month average over 366 days less the 9-month over 274, the two on one basis (x30).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Cocrystal Pharma's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| COCPCocrystal Pharma | $18.3M | n/m | 129× | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Cocrystal Pharma
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .